Aurinia to Host Annual General Meeting of Shareholders and Webcast on June 21 in Vancouver, BC Jun 21, 2017
Aurinia Presents Additional Data from Phase Iib Aura-Lv Study, Demonstrating Stable Renal Function and Blood Pressure without Electrolyte Complications Through 48 Weeks Jun 5, 2017
Aurinia to Participate in Late Breaking Oral Presentations at Two Upcoming Scientific Conferences May 30, 2017
Aurinia Doses First Patient in AURORA Phase 3 Clinical Trial of Voclosporin in Lupus Nephritis May 17, 2017
Aurinia Reports First Quarter 2017 Financial Results, Announces Initiation of Phase III Aurora Clinical Trial, and Provides Operational Highlights May 15, 2017
Aurinia Releases Additional 48-Week Data from the AURA-LV Study During Late-Breaking Session at the National Kidney Foundation 2017 Spring Clinical Meetings Apr 20, 2017
Aurinia Completes Licensing Deal with Merck Animal Health for Its Nanomicellar Formulation of Voclosporin for the Treatment of Canine Dry Eye Syndrome Apr 17, 2017
